» Articles » PMID: 7538534

Expansion of Immunostimulatory Dendritic Cells Among the Myeloid Progeny of Human CD34+ Bone Marrow Precursors Cultured with C-kit Ligand, Granulocyte-macrophage Colony-stimulating Factor, and TNF-alpha

Overview
Journal J Immunol
Date 1995 Jun 1
PMID 7538534
Citations 50
Authors
Affiliations
Soon will be listed here.
Abstract

Human CD34+ bone marrow progenitors cultured in the presence of granulocyte-macrophage CSF (GM-CSF) develop along a myeloid pathway, and the addition of exogenous TNF-alpha leads to the differentiation of dendritic cells among the myeloid progeny. These bone marrow CD34+ -derived dendritic cell that develop during 2-wk culture have the same morphologic, phenotypic, and functional properties that distinguish mature dendritic cells in blood. c-kit ligand does not directly influence dendritic cell differentiation per se, but rather increases the total cell number in synergistic combination with GM-CSF and TNF-alpha. This degree of expansion translates into an effective yield of approximately 1.7 x 10(6) mature dendritic cells per single ml of normal adult human bone marrow, compared with approximately 10(6) dendritic cells usually obtained from 450 to 500 ml of peripheral blood. In addition to dendritic cells that constitute approximately 10 to 15% of the total myeloid progeny, the cultures contain monocytes/macrophages and intermediate granulocytic precursors. Monocytes/macrophages and dendritic cells together comprise all of the class II MHC-positive progeny. Sorted cells bearing the CD14+ HLA-DR+ phenotype of mature monocytes are at least 1.5 to 2 logs less active than CD14- HLA-DR+ dendritic cells as stimulators in the allogeneic MLR, even though both CD14+ and CD14- subpopulations share expression of several costimulatory ligands. The synergistic combination of c-kit ligand, GM-CSF, and TNF-alpha therefore expands substantial numbers of immunostimulatory CD14- HLA-DR+ dendritic cells from defined CD34+ progenitors in human bone marrow. This should facilitate the use of dendritic cells in the manipulation of T cell-mediated immune responses.

Citing Articles

Prevalence of the fusion gene and T cell stimulation capacity of dendritic cells in chronic myelogenous leukemia.

Gaafar A, Al-Omar H, Manogaran P, Almohareb F, Alhussein K Am J Transl Res. 2023; 15(2):967-981.

PMID: 36915720 PMC: 10006767.


Comparison of efficacy and tolerability of adjuvant therapy for resected high-risk stage III-IV cutaneous melanoma: a systemic review and Bayesian network meta-analysis.

Ba H, Zhu F, Zhang X, Mei Z, Zhu Y Ther Adv Med Oncol. 2023; 15:17588359221148918.

PMID: 36743526 PMC: 9893404. DOI: 10.1177/17588359221148918.


AKT Isoforms in the Immune Response in Cancer.

Ahmad Z, Somanath P Curr Top Microbiol Immunol. 2022; 436:349-366.

PMID: 36243852 DOI: 10.1007/978-3-031-06566-8_15.


Effects of disodium cantharidinate on dendritic cells of patients with bladder carcinoma.

Zang G, Li R, Zhou R, Hao L, He H, Zhang W Oncol Lett. 2018; 15(2):2273-2277.

PMID: 29434934 PMC: 5777130. DOI: 10.3892/ol.2017.7589.


The Ability of Precursory Monocytes (MO) to Differentiate Varies Among Individuals But Is Stable Over Time.

Laudanski K, Zawadka M, Lapko N Med Sci Monit. 2016; 22:2463-70.

PMID: 27415582 PMC: 4957624. DOI: 10.12659/msm.898256.